Vistagen reports fiscal year 2024 financial results and provides corporate update

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year ended march 31, 2024, and provided a corporate update. “vistagen's fiscal 2024 proved to be a year full of remarkable accomplishments. most notably, with.
VTGN Ratings Summary
VTGN Quant Ranking